Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita (original) (raw)

• Armanios M . Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009; 10: 45–61.
  Article CAS Google Scholar
• Walne A, Dokal I . Advances in the understanding of dyskeratosis congenita. Br J Haematol 2009; 145: 164–172.
  Article CAS Google Scholar
• Savage S, Alter B . Dyskeratosis congenita. Hematol Oncol Clin North Am 2009; 23: 215–231.
  Article Google Scholar
• Palm W, de Lange T . How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42: 301–334.
  Article CAS Google Scholar
• Savage S, Giri N, Baerlocher G, Orr N, Lansdorp P, Alter B . TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008; 82: 501–509.
  Article CAS Google Scholar
• MacMillan ML, Blazar BR, DeFor T, Ma L, Tolar J, Zierhut H et al. Alternate donor HCT for fanconi anemia (FA): results of a total body irradiation (TBI) dose de-escalation study. ASH Ann Meet Abst 2008; 112: 298–299.
  Google Scholar
• Savage S, Dokal I, Armanios M, Aubert G, Cowen E, Domingo D et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer 2009; 53: 520–523.
  Article Google Scholar
• Wagner J, Eapen M, MacMillan M, Harris R, Pasquini R, Boulad F et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109: 2256–2262.
  Article CAS Google Scholar
• de la Fuente J, Dokal I . Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007; 11: 584–594.
  Article CAS Google Scholar
• Alter B, Giri N, Savage S, Rosenberg P . Cancer in dyskeratosis congenita. Blood 2009; 113: 6549–6557.
  Article CAS Google Scholar
• Kirwan M, Dokal I . Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009; 1792: 371–379.
  Article CAS Google Scholar
• Amarasinghe K, Dalley C, Dokal I, Laurie A, Gupta V, Marsh J . Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant 2007; 40: 913–914.
  Article CAS Google Scholar
• Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389–392.
  Article CAS Google Scholar
• Brazzola P, Duval M, Fournet J, Gauvin F, Dalle J, Champagne J et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant 2005; 36: 1103–1105 (author reply 1105).
  Article CAS Google Scholar
• Alter B, Baerlocher G, Savage S, Chanock S, Weksler B, Willner J et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007; 110: 1439–1447.
  Article CAS Google Scholar
• Scharf S, Smith A, Hansen J, McFarland C, Erlich H . Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995; 85: 1954–1963.
  CAS Google Scholar
• Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
  Article Google Scholar
• Straathof K, Rao K, Eyrich M, Hale G, Bird P, Berrie E et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009; 374: 912–920.
  Article CAS Google Scholar
• Dror Y, Freedman M, Leaker M, Verbeek J, Armstrong C, Saunders F et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 847–850.
  Article CAS Google Scholar
• Cossu F, Vulliamy T, Marrone A, Badiali M, Cao A, Dokal I . A novel DKC1 mutation, severe combined immunodeficiency (T+B-NK- SCID) and bone marrow transplantation in an infant with Hoyeraal-Hreidarsson syndrome. Br J Haematol 2002; 119: 765–768.
  Article CAS Google Scholar
• Coman D, Herbert A, McGill J, Lockwood L, Hallahan A . Unrelated cord blood transplantation in a girl with Hoyeraal-Hreidarsson syndrome. Bone Marrow Transplant 2008; 42: 293–294.
  Article CAS Google Scholar
• Ostronoff F, Ostronoff M, Calixto R, Florêncio R, Domingues M, Souto Maior A et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. Biol Blood Marrow Transplant 2007; 13: 366–368.
  Article Google Scholar
• Ghavamzadeh A, Alimoghadam K, Nasseri P, Jahani M, Khodabandeh A, Ghahremani G . Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. Bone Marrow Transplant 1999; 23: 299–301.
  Article CAS Google Scholar
• Ayas M, Al-Musa A, Al-Jefri A, Al-Seraihi A, Al-Mahr M, Rifai S et al. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin. Pediatr Blood Cancer 2007; 49: 103–104.
  Article CAS Google Scholar
• Güngör T, Corbacioglu S, Storb R, Seger R . Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of Dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 407–410.
  Article Google Scholar
• Nobili B, Rossi G, De Stefano P, Zecca M, Giorgiani G, Perrotta S et al. Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. Br J Haematol 2002; 119: 573–574.
  Article Google Scholar
• Kang S, Kirkpatrick J, Halperin E . Low-dose radiation for posttransplant lymphoproliferative disorder. Am J Clin Oncol 2003; 26: 210–214.
  Article Google Scholar
• Ruggeri A, de Latour R, Rocha V, Larghero J, Robin M, Rodrigues C et al. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol 2008; 143: 404–408.
  Article CAS Google Scholar
• Langston A, Sanders J, Deeg H, Crawford S, Anasetti C, Sullivan K et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758–765.
  Article CAS Google Scholar
• Chan K, Li C, Worth L, Chik K, Jeha S, Shing M et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant 2001; 27: 125–128.
  Article CAS Google Scholar
• Sampath S, Schultheiss T, Wong J . Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63: 876–884.
  Article Google Scholar
• Grochow L, Jones R, Brundrett R, Braine H, Chen T, Saral R et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55–61.
  Article CAS Google Scholar
• Samuels B, Bitran J . High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786–1799.
  Article CAS Google Scholar
• Akasheh M, Freytes C, Vesole D . Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 1107–1109.
  Article CAS Google Scholar
• Rocha V, Devergie A, Socié G, Ribaud P, Espérou H, Parquet N et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243–248.
  Article CAS Google Scholar
• Weaver T, Kirk A . Alemtuzumab. Transplantation 2007; 84: 1545–1547.
  Article CAS Google Scholar
• Siegal D, Xu W, Sutherland R, Kamel-Reid S, Kuruvilla J, Lipton J et al. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008; 42: 51–56.
  Article CAS Google Scholar
• Landgren O, Gilbert E, Rizzo J, Socié G, Banks P, Sobocinski K et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992–5001.
  Article CAS Google Scholar
• Myers G, Krance R, Weiss H, Kuehnle I, Demmler G, Heslop H et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36: 1001–1008.
  Article CAS Google Scholar
• Mathew C . Fanconi anaemia genes and susceptibility to cancer. Oncogene 2006; 25: 5875–5884.
  Article CAS Google Scholar
• Alter B . Cancer in Fanconi anemia, 1927–2001. Cancer 2003; 97: 425–440.
  Article Google Scholar
• Calado R, Young N . Telomere maintenance and human bone marrow failure. Blood 2008; 111: 4446–4455.
  Article CAS Google Scholar
• Fogarty P, Yamaguchi H, Wiestner A, Baerlocher G, Sloand E, Zeng W et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003; 362: 1628–1630.
  Article CAS Google Scholar